Fig. 3: Optimal priming of antigen-specific CD8+ T cells by anti-mCD27 requires tetravalency and FcγR engagement.
From: Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy
A–C C57BL/6 mice received OT-I Tg CD45.1+ cells on day 0, followed by OVA257–264 peptide and the indicated antibodies on day 1. Expansion of OVA257–264 specific CD45.1+ CD8+ T cells was monitored by flow cytometry of peripheral blood samples following staining with anti-CD8 and anti-CD45.1. A Representative flow cytometry contour plots obtained on day 5 and B the compiled data with each bar representing the mean ± SEM from 4 individual mice from one experiment (n = 4 mice per group). Statistical significance was determined by one-way ANOVA, with Tukey’s post-hoc test for multiple comparisons, and significance values are indicated in the figure. C Time course of CD45.1+ CD8+ T cell expansion. Data points are the mean ± SEM from 4 individual mice from one experiment (n = 4 mice per group). Statistical significance was assessed by one-way ANOVA with Tukey’s post-hoc test for multiple comparisons on areas under the curve (AUC), with significance values indicated in the figure. Responses of “NQ” antibody variants were not statistically significant compared to the isotype control. Source data are provided as a Source data file.
